Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
121 words
A method for producing human-human hybridomas producing specific human monoclonal antibodies against a predefined determinant site which comprises: fusing lymphoid cells immunized against a predefined determinant site with rapidly growing HAT 'sensitive non-Epstein-Barr virus transformed neoplastic lymphoid cell in a fusing medium at an approximately equivalent cell ratio to produce a cell mixture; dividing into each of a plurality of wells a sufficient number of cells of said cell mixture to encourage growth and incubating said cells in a nutrient medium for a sufficient time to expand the number of viable cells in each well; growing the cells in HAT medium to produce clones free of HAT sensitive cells; and selecting for clones producing monoclonal antibodies for said predefined determinant site.
Claim 2
Independent Claim
121 words
A method for producing human-human hybridomas producing specific human monoclonal antibodies against a predefined determinant site which comprises: fusing lymphoid cells immunized against a predefined determinant site with rapidly growing HAT 'sensitive non-Epstein-Barr virus transformed neoplastic lymphoid cell in a fusing medium at an approximately equivalent cell ratio to produce a cell mixture; dividing into each of a plurality of wells a sufficient number of cells of said cell mixture to encourage growth and incubating said cells in a nutrient medium for a sufficient time to expand the number of viable cells in each well; growing the cells in HAT medium to produce clones free of HAT sensitive cells; and selecting for clones producing monoclonal antibodies for said predefined determinant site.
Claim 3
Dependent Claim
26 words
A method according to Claim 1, wherein said neoplastic lymphoid cells are HAT sensitive myeloma cells which are grown in the presence of 8-azaguanine before fusing.
Claim 4
Dependent Claim
26 words
A method according to Claim 1, wherein said neoplastic lymphoid cells are HAT sensitive lymphoma cells, which are grown in the presence of 8-azaguanine before fusing.
Claim 5
Dependent Claim
8 words
Human monoclonal antibodies derived from a human-human hybridoma.
Claim 6
Dependent Claim
8 words
Human monoclonal antibodies derived from a human-human hybridoma.
Claim 7
Dependent Claim
20 words
Antibodies according to Claim 4, wherein said human-human hybridoma is derived from non-Epstein-Barr virus transformed neoplastic lymphoid cell fusion partners.
Claim 8
Dependent Claim
15 words
Antibodies according to Claim 5, wherein said human-human hybridoma is derived from a myeloma cell.
Claim 9
Dependent Claim
17 words
. Human monoclonal antibodies according to any of Claims 4 to 6, wherein said antibodies are IgM.
Claim 10
Dependent Claim
16 words
Human monoclonal antibodies according to any of Claims 4 to 6, wherein said antibodies are IgA.
Claim 11
Dependent Claim
11 words
Myeloma cells of the U-266-AR l strain or cells derived therefrom.
Claim 12
Dependent Claim
11 words
Myeloma cells of the U-266-AR l strain or cells derived therefrom.
Claim 13
Dependent Claim
3 words
Human hybridoma cells
Claim 14
Dependent Claim
3 words
Human hybridoma cells
Claim 15
Independent Claim
46 words
A method for treating a human host subject to an undesirable physiological response from contact with a surface antigen of a pathogenic cell, which comprises: administering to said human host human monoclonal antibodies specific for said antigen in an amount sufficient to diminish said undesirable response.
Claim 16
Independent Claim
46 words
A method for treating a human host subject to an undesirable physiological response from contact with a surface antigen of a pathogenic cell, which comprises: administering to said human host human monoclonal antibodies specific for said antigen in an amount sufficient to diminish said undesirable response.
Claim 17
Dependent Claim
37 words
A composition of matter consisting essentially of human IgG molecules characterized by being: a) substantially free of incomplete IgG molecules; b) homogeneous in chemical composition; and c) specifically binding to a predefined determinant site on an antigen.
Claim 18
Dependent Claim
37 words
A composition of matter consisting essentially of human IgG molecules characterized by being: a) substantially free of incomplete IgG molecules; b) homogeneous in chemical composition; and c) specifically binding to a predefined determinant site on an antigen.